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Long non-coding RNA XIST regulates PTEN
expression by sponging miR-181a and
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Abstract
Background: Tumor metastasis often occurs in hepatocellular carcinoma (HCC) and influences the patient’s
prognosis, and microRNAs are reported to play key roles in tumor metastasis. This study was conducted to explore
the effect of microRNAs on HCC metastasis.
Methods: The levels of miR-181a in HCC tissues, adjacent tissues, metastatic HCC tissues, and non-metastatic HCC
tissues at different stages were determined by qRT-PCR. Effect of miR-181a on the proliferation, invasion, and
metastasis of HCC cells was estimated by cell counting kits-8 (CCK-8), wound-healing, and Transwell assays.
Software analysis and luciferase assays were used to explore the target gene of miR-181a.
Results: MiR-181a was up-regulated in HCC tissues and its expression level in metastatic HCC tissues was much
higher than in non-metastasis samples. PTEN was found to be a target gene of miR-181a. MiR-181a had multiple
binding sites with the long non-coding RNA (lncRNA) XIST. The regulation of miR-181a on PTEN was mediated by
lncRNA XIST. The proliferation and invasion of cells with siXIST were significantly enhanced compared with those of
control cells, while knockdown of miR-181a abolished the enhancing effects.
Conclusions: MiR-181a can promote HCC metastasis by targeting PTEN, which is regulated by lncRNA XIST.
Keywords: MicroRNA-181a, Hepatocellular carcinoma (HCC), Metastasis, PTEN, XIST
Background
Hepatocellular carcinoma (HCC) is one of the most ubi-
quitous tumors in the world [1]. It grows rapidly and
has a high propensity for metastasis, which worsens the
prognosis of patients with this neoplasm [2]. Therefore,
HCC metastasis is a significant problem that needs to be
addressed [3]. However, the molecular mechanisms by
which HCC metastasis occurs are still unknown and
need to be elucidated.
Epithelial-to-mesenchymal transition (EMT) plays an
important role in regulating metastasis and invasion by
malignant tumors [4], including HCC [5]. Many factors
have been reported to influence EMT, including signal-
ing pathways and microRNAs. Moreover, previous
studies showed that abnormal expression of some micro-
RNAs (miRNAs) were related with the development of
HCC [6]. Philip et al. [7] reported that the miR-200
family and miR-205 can regulate EMT by targeting
ZEB1 and SIP1 (SIP1, also named ZEB-2, is a smad-
interacting, multi-zinc finger protein that shows specific
DNA binding activity). Adam et al. [8] reported mem-
bers of the miR-200 family appear to control the EMT
process in bladder cancer cells. Zhang et al. [9] reported
miR-27 plays an important role in regulating metastasis
of gastric cancer by inducing EMT. In hepatocytes, miR-
30 can inhibit TGF-β1-induced EMT by targeting Snail1
(Snail1 is a zinc finger transcriptional repressor whose
pathological expression has been linked to cancer cell)
[10]. Moreover, in HCC, miR-490-3p can modulate cell
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growth and EMT of HCC cells by targeting endoplasmic
reticulum-golgi intermediate compartment protein 3
(ERGIC3) [11]. However, the changes in miRNA expres-
sion in response to EMT are highly complex and
variable.
In the present study, we used Hsa-miR-181a-5p, which
is a mature product of hsa-miR-181a with a sequence of
24-AACAUUCAACGCUGUCGGUGAGU-46. We found
that miR-181a was up-regulated in the tumor tissues of
HCC patients and promoted the proliferation and metas-
tasis of HCC cells in vitro and in vivo. We investigated the
molecular mechanism of miR-181a in the progression of
HCC and the reciprocal regulation between miR-181a and
the long non-coding RNA (lncRNA) XIST.
Methods
Identification of differentially expressed miRNA
The gene expression profiles of HCC patients with nor-
mal controls were downloaded from Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo) with acces-
sion number of GSE77314. This dataset was based on
the platform of IlluminahumanHT-12 v4.0 expression
beadchip deposited by Seok et al. [12]. In their study,
Seok et al. focused on comparing molecular features of
scirrhous hepatocellular carcinoma with those of hepato-
cellular carcinoma and CC. The original dataset included
26 genechips, and we extracted 11 of them for further
analysis, including 6 from CC cancer tissue and 5 from
the surrounding normal liver.
We transferred the probe-level data in CEL files into
expression measures. Then, background was corrected
and quartile data was normalized by the robust multi-
array average (RMA) algorithm. The file in the platform
annotation files provided by the Affymetrix Company
was used to map the relationship between the probes
and gene symbols. A probe would be filtered if it did not
have corresponding gene symbols. The average value of
gene symbols with multiple probes obtained was then
further analyzed. A set of gene-specific t-tests with the
threshold of false discovery rate (FDR) ≤ 0.05 was assim-
ilated to identify differentially expressed miRNA.
Tissue samples
We collected both cancer tissue and adjacent normal tis-
sue from 55 HCC patients who underwent surgery in
the Ji’nan Infectious Disease Hospital between February
2013 and November 2015. Before the surgery, they had
no chemotherapy or radiotherapy performed. After re-
section, the tissues were stored at −80 °C. The stages of
tissues were distinguished based on the seventh edition
of the American Joint Committee on Cancer (AJCC)
tumor node-metastasis (TNM) staging system.
This study was approved by the Ethics Committees of
Ji’nan Infectious Disease Hospital. Informed consent was
obtained from each patient, including consent for their
samples to be taken and used for research purposes.
Cell culture
Human HCC cell lines HCCLM3, HepG2, Hep3B,
SMMC-7721, and Huh7 as well as normal liver cell lines
HL-7702 and L-02 were purchased from the Cell Bank
of the Chinese Academy of Sciences (Shanghai, China).
All cells were kept in Dulbecco’s Modified Eagle’s
Medium (DMEM, Gibco, USA) in humidified air con-
taining 5% CO2 at 37 °C. This medium contained 10%
fetal bovine serum (FBS) (Hyclone, USA) and 1% penicil-
lin/streptomycin.
Cell transfection
Cells were seeded into 6-well plates and transfected
with miR-181a mimics, miR-181a inhibitor, or normal
control (NC) using Lipofectamine 2000 (Invitrogen,
USA). For inhibiting endogenous lncRNA XIST ex-
pression, siRNA targeting XIST was purchased from
Shanghai GenePharma, China. The partial sequences
used in this study are shown in Additional file 1:
Table S1.
RNA isolation and quantitative RT-PCR
RNA of microRNA used for detection was extracted from
tissues or cell lines using a mirVana miRNA isolation kit.
RNA of mRNA used for detection was extracted from tis-
sues or cell lines using the TRIzol method. TRIzol (1 mL)
was added and the solution was mixed for 10 min until it
was homogeneous. The mixture was then transferred into
Eppendorf tubes (EP, 1.5 mL) with 200 μl chloroform.
After shaking for 15 min, the EP tubes were centri-
fuged at 4 °C for 15 min (12,000×g). The supernatant
was transferred into other EP tubes and mixed with
isopycnic isopropanol for 15 s. The mixture was then
centrifuged at 4 °C for 10 min (12,000×g). The super-
natant was discarded and the precipitate was washed
with 75% ethanol twice and dissolved into 30 μl
diethylpyrocarbonate (DEPC) after drying to obtain an
RNA stock solution. After isolation, the concentration
of RNA was determined using a NanoDrop 1000 spec-
trophotometer (NanoDrop Technologies, Wilmington,
Delaware, USA), and the RNA solution was stored at
−80 °C for further use.
For qRT-PCR, genes were amplified by specific oligo-
nucleotide primers, and the human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene was used as
an endogenous control. The sequences of primers and
probes used for the qRT-PCR analysis are shown in
Additional file 2: Table S2. The detection and quantifica-
tion entailed the following steps: (1) reverse transcrip-
tion was performed at 55 °C for 30 min, (2) initial
activation for 15 min at 95 °C, (3) 40 cycles of
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denaturation conducted at 94 °C for 15 s, (4) annealing
for 30 s at 55 °C, and (5) extension for 30 s at 72 °C.
The expression level was normalized using U6 small nu-
clear RNA by the 2−ΔCt method.
Western blotting
Cells were inoculated to 6-well plates with each plate of
5 × 105 cells and cultivated for 24 h. The culture solu-
tion was absorbed away and cells were rinsed with ice
PBS for 3 times. Then radio immunoprecipitation assay
(RIPA) was added to each well to obtain total proteins;
12% separation gel and 5% spacer gel was then used to
perform SDS-PAGE gel electrophoresis. Samples were
transferred to nitrocellulose filter membranes (Hybond,
Escondido, CA, USA). The membranes was placed in
tris-buffered saline Tween-20 (TBST) containing 5%
skim milk powder and blocked for 1 h at room
temperature. After 1 h, membranes were taken out and
rinsed with TBST once. Antibodies were diluted with 5%
bovine serum albumin (BSA), and membranes were
placed in antibody with the appropriate concentration.
Primary antibodies were determined using an EZ-ECL
chemiluminescence Detection kit for HRP (Biological
Industries, Beit-Haemek, Israel).
Cell viability assay
Cells were seeded in the 96-well plate for 24 h after
transfection at a density of 1500 cells/well. The cell via-
bility assay was performed using a Cell Counting Kit-8
(CCK8; Dojindo) according to the manufacturer’s proto-
col. The absorbance at 450 nm was measured. Experi-
ments were performed in triplicate.
Wound healing assay
After transfection of miR-181a mimics, miR-181a inhibi-
tor or NC, HCCLM3 and Huh7 cells (1 × 106/well) were
inoculated to 6-well plates. Wounds were imposed by
dragging a 1000-μl pipette tip through the cell mono-
layer. Cells were allowed to migrate for 36 h. The gap
area was then photographed, and migration distances
were measured.
Cell invasion assay
Invasion activity of the cells was determined with a
cell invasion assay according to the manufacturer’s in-
structions (BD Biosciences, San Jose, CA, USA).
Briefly, HCCLM3 and Huh7 cells (5 × 104/well) were
seeded in the upper chamber insert with 1% FBS
medium after transfection, while the lower chamber
insert contained complete culture medium with 10%
FBS medium to trap invading cells. After incubation
for 24 h, cells that penetrated the Matrigel-coated
membranes and migrated into the lower chamber were
stained with crystal violet (0.1%) and photographed. In
each sample, invasion ability was quantified by count-
ing crystal violet-stained cells.
Luciferase activity assays
The 3′-UTR of PTEN sequence was cloned into the
pGL3-basic luciferase reporter vector (Promega, USA).
For the luciferase assays, 100 ng PGL3-PTEN-3’UTR vec-
tor was co-transfected in cells with 100 nM miR-181a
mimics or control regent, together with 20 ng Renilla
luciferase vector (Promega, USA) as an internal
normalized control. Cells were harvested after trans-
fection for 48 h, and their luciferase activities were
determined according to the manufacturer’s protocol.
Transfections were performed in duplicate and re-
peated three times.
Tumor size and weight
After HCC cell lines were transfected with miR-181a
mimics or miR-181a inhibitor for 1, 2, 3, 4, or 5 days, we
determined the tumor size and tumor weight, and com-
pared them with those of the controls. The tumor size
was determined by three-dimensional ultrasound, and
tumor weight was determined by a precision electronic
balance.
Statistical analysis
Statistical analyses were performed using SPSS (SPSS
Inc., Chicago, IL, USA). All data were expressed as
mean ± standard deviation. Student’s t-test or a one-way
ANOVA test was performed to determine significant
differences; a p < 0.05 was considered statistically
significant.
Results
MiR-181a was up-regulated in HCC metastasis patients
To explore whether and how miRNAs play key roles in
HCC, miRNA data were downloaded from the database
and uploaded to GEO (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE77314) to screen differentially
expressed genes. Results showed 16 miRNAs were
down-regulated and 34 miRNAs were up-regulated
(Fig. 1a). Among the 34 up-regulated miRNAs, the
degree of up-regulation of miR-181a was the most
marked. To explore the influence of miR-181a on
HCC, 55 HCC tissue samples and the adjacent nor-
mal tissues were selected. The relative mRNA level of
miR-181a in them was determined and compared. Re-
sults showed the level of miR-181a in HCC tissues
was significantly higher than that in the adjacent tis-
sues (Fig. 1b). To study the relationship between
miR-181a and tumor metastasis, we studied the level
of miR-181a in the invasive and normal tissues. Re-
sults showed the miR-181a expression levels in meta-
static HCC tissues were dramatically higher than
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those in non-metastatic HCC tissues (Fig. 1c). More-
over, the levels of miR-181a in HCC tissues at differ-
ent stages were also determined by qRT-PCR. Results
showed the level of miR-181a in stage III and IV was
markedly higher than that during stage I and II (Fig. 1d).
It indicated miR-181a may be closely related to the TNM
stage of HCC. Then the level of miR-181a in serum of
HCC patients was determined and compared with normal
levels. The results showed that the miR-181a level in HCC
serum was significantly higher than normal (Fig. 1e).
Moreover, the level of miR-181a was positively related
with alpha feto protein (AFP) (Fig. 1f). AFP is a fetal
glycoprotein produced by the yolk sac and fetal liver. It
was reported to have a role in diagnosing and managing
HCC [13]. These results indicated miR-181a is a potential
biomarker to aid in HCC detection.
Knockdown of miR-181a inhibited the proliferation,
mobility, and invasion of HCC cells
To investigate the role of miR-181a in the development
and progression of HCC, we measured miR-181a expres-
sion levels in various HCC cell lines (HCCLM3, HepG2,
Fig. 1 Expression levels of miR-181a in HCC tissues and plasma samples. a Partial miRNAs expression profiles of HCC tissues. b Relative expression
level of miR-181a in HCC tissues and normal liver tissues. c Relative expression level of miR-181a in HCC metastatic and non-metastatic tissues. d
Relative expression level of miR-181a in different TNM stage. e Relative expression level of miR-181a in serum of HCC patients and normal. f The
positive correlation between AFP and miR-181a levels in the plasma of HCC patients. HCC, hepatocellular carcinoma
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Hep3B, SMMC-7721, and Huh7) and normal liver cell
lines (HL-7702 and L-02). Among these cell lines,
HCCLM3 is a poorly differentiated HCC cell line with
strong metastatic potential. Huh7 is a well-differentiated
HCC cell line with weak metastatic ability. The results
showed that in HCC cell lines, the relative expression of
miR-181a in HCCLM3 cells was the highest, while the
value in Huh7 cells was the lowest (Fig. 2a). HCCLM3
and Huh7cells were selected for further study. MiR-181a
inhibitor was used to reduce the level of miR-181a in
HCCLM3 cells, and miR-181a level was increased by
miR-181a mimics in Huh7 cells. The transfection effect
is illustrated in Additional file 3: Figure S1. As shown,
the miR-181a inhibitor significantly decreased miR-181a
level in HCCLM3 cells compared with the inhibitor NC
group, whereas miR-181a mimics observably increased
miR-181a level in Huh7 cells compared with the NC
mimic group. When the proliferation capacity of
HCCLM3 cells after transfection with miR-181a inhibi-
tor for 24, 36, and 48 h was determined, cell growth de-
creased significantly after transfection with miR-181a
inhibitor for 36 and 48 h (Fig. 2b). To verify the relation-
ship between miR-181a and tumor growth, the level of
miR-181a in Huh7 cells was increased by transfection
with miR-181a mimics and cell viability was determined
after 24, 36, and 48 h. Results showed the cell vitality
increased after transfection with miR-181a mimics
(Fig. 2c). Moreover, a wound-healing assay showed
that knockdown of miR-181a drastically suppressed
the mobility of HCCLM3 cells compared with control
cells, whereas miR-181a overexpression promoted the
mobility of Huh7 cells (Fig. 2d and e). Transwell as-
says demonstrated that knockdown of miR-181a sig-
nificantly inhibited the invasion of HCCLM3 cells
compared with that of the control cells, while miR-
181a overexpression promoted the invasion of Huh7-
cells (Fig. 2f). Results of tumor size showed knockdown of
miR-181a significantly reduced the tumor size compared
with the control, while overexpression of miR-181a in-
creased tumor size (Fig. 3a and b). Moreover, results of
tumor weight also showed that knockdown of miR-181a
dramatically reduced the tumor weight compared with the
control, while overexpression of miR-181a increased
tumor weight (Fig. 3c and d).
MiR-181a regulated EMT by PI3K/AKT signaling pathway
E-cadherin is a marker of epithelial cells, and MMP-2
and MMP-9 are markers of mesenchymal cells. Their
changes correlated with EMT [14]. We examined the ex-
pression of EMT markers (Snail, Slug, N-cadherin,
Vimentin, and E-cadherin), MMP-2, and MMP-9 in
HCCLM3 and Huh7 cells. The results showed the ex-
pression of Snail, Slug, N-cadherin, Vimentin, MMP-2,
and MMP-9 in HCCLM3 cells decreased after the
knockdown of miR-181a, while the expression of E-
cadherin increased. In Huh7 cells, we found increased
expression of Snail, Slug, N-cadherin, Vimentin, MMP-2,
and MMP-9 but E-cadherin expression decreased after
transfection with miR-181a mimics (Fig. 4a). Many stud-
ies have shown that GSK3b is a target of PI3K/Akt and
can regulate MMPs [15]. We examined the effect of
miR-181a on AKT signaling pathway and found that
knockdown of miR-181a significantly decreased the
expression of phosphorylated AKT and mTOR in
HCCLM3 cells, whereas overexpression of miR-181a sig-
nificantly increased the expression of phosphorylated
AKT and mTOR in Huh7 cells (Fig. 4b).
PTEN is a direct target of miR-181a in HCC
By target gene prediction analysis, we found that there
were binding sites between PTEN and microRNA. PTEN
is a phosphatase with a sequence similar to that of the
cytoskeletal protein tensin. Lee et al. [16] reported that
in ovarian cancer, reduction of PTEN can activate the
PI3K/Akt pathway. Moreover, treatment of PTEN-
positive T-ALL cells can down-regulate constitutive
phosphorylation of Akt in many leukemia/lymphoma
cell lines [17]. Therefore, we selected PTEN for further
study. As Fig. 5a showed, PTEN may be a target gene of
miR-181a (Fig. 5a). The luciferase assay showed the
miR-181a mimic inhibited the luciferase activity of
PTEN 3′-UTR wt (wild type), but had no influence on
the luciferase activity of PTEN 3′-UTR mut (mutant).
MiR-181a inhibitor promoted the luciferase activity of
PTEN 3′-UTR wt while it had no influence on the lucif-
erase activity of PTEN 3′-UTR mut (Fig. 5b). Moreover,
transfection with miR-181a mimics could significantly
decrease PTEN expression, although transfection with
miR-181a inhibitor significantly increased PTEN expres-
sion (Fig. 5c and d). The results of immunohistochemis-
try studies (Fig. 5e) showed PTEN staining decreased
when the expression of miR-181a was low. All these re-
sults indicated PTEN was a target gene of miR-181a.
Reciprocal repression between XIST and miR-181a in HCC
cells
Recent studies showed that microRNA-92b can promote
HCC progression by targeting Smad7, mediated by
lncRNA XIST [18]. So we explored whether the regula-
tion on PTEN by miR-181a is regulated by lncRNA.
Using bioinformatics analysis, we found binding sites be-
tween miR-181a and lncRNA XIST, and thus carried out
the follow-up study. To explore the interaction between
XIST and miR-181a, we constructed three reporter plas-
mids separately containing one predicted miR-181a
binding site on the mRNA of XIST, and three corre-
sponding reporter plasmids with mutant miR-181a bind-
ing sites (Fig. 6a). The results of the three binding sites
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were same (data not shown) so one binding site was se-
lected for further study. Luciferase reporter gene assay
showed that miR-181a could significantly inhibit the re-
porter activities of wt-XIST but not mut-XIST (Fig. 6b).
We subsequently detected the expression of XIST in
normal liver cells L-02 and HL-7702, and in HCC cells
HCCLM3 and Huh7. The results showed the level of
XIST in normal liver cells was markedly higher than that
in HCC cells. Moreover, the level in Huh7 cells was sig-
nificantly higher than that in HCCLM3 cells (Fig. 6c).
Transfection was used to change the level of XIST in
HCC cells. The XIST level in Huh7 cells decreased
significantly after transfection with si-XIST (Additional
file 4: Figure S2A), whereas XIST level in HCCLM3 cells
increased markedly after transfection with pcDNA-XIST
(Additional file 4: Figure S2B). Figure 6d shows that the
level of XIST in the miR-181a inhibitor group increased
significantly compared with both the blank and the
inhibitor NC group. The relative expression of miR-181a
increased markedly in si-XIST group compared with the
blank group (Fig. 6e). Then, we used RT-PCR to deter-
mine the relative expression of XIST and the results
showed the level in HCC tissues was lower than that in
normal tissues (Fig. 6f ). The relationship between the
relative expression of XIST and miR-181a was determined,
and the results showed that the level of XIST was in-
versely proportional to the miR-181a level (Fig. 6g).
LncRNA XIST regulated HCC via miR-181a
To explore the relationship between lncRNA XIST and
miR-181a, the protein expression values of PTEN in
HCCLM3 cells after transfection with pcDNA-XIST,
pcDNA-mut-XIST, miR-181a mimic, miR-181a mimic +
pcDNA-XIST, and miR-181a mimic + pcDNA-mut-XIST
were determined by western blotting. The results
showed that the expression value of PTEN in the
(See figure on previous page.)
Fig. 2 MiR-181a regulated the proliferation and invasion of HCC cells. a Relative expression level of miR-181a in HCC cell lines with high or low
metastatic capacity and normal liver cells. b The proliferation of HCCLM3 cells with strong metastatic capacity was reduced after knockdown of
miR-181a. c The proliferation of Huh7 cells with weak metastatic capacity was increased after the overexpression of miR-181a. d and e Representative
micrographs of wound healing assay of HCCLM3 and Huh7 cells stably expressing miR-181a. f The effects of miR-181a overexpression or knockdown
on invasion of HCCLM3 or Huh7 cells were analyzed using Transwell assays. HCC, hepatocellular carcinoma. All values are mean ± SD. * vs inhibitor NC,
p < 0.05. ** vs inhibitor NC, p < 0.01
Fig. 3 MiR-181a increased tumor size and weight. a Tumor size after transfection with inhibitor NC or miR-181a inhibitor. b Tumor size after
transfection with mimics NC or miR-181a mimics. c Tumor weight after transfection with inhibitor NC or miR-181a inhibitor. d Tumor weight after
transfection with mimics NC or miR-181a mimics. ** vs inhibitor NC or mimics NC, p < 0.01. *vs inhibitor NC or mimics NC, p < 0.05
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miR-181a mimic group was decreased and in the
pcDNA-XIST group it was increased compared with
the blank group. However, the inhibition of miR-181a
mimic on PTEN was abolished by pcDNA-XIST,
while further use of pcDNA-mut-XIST had no influ-
ence on the inhibition effect of miR-181a mimic on
PTEN (Fig. 7a). Moreover, the protein expression
value of PTEN was decreased by si-XIST and in-
creased by miR-181a inhibitor, and the promotion of
miR-181a inhibitor on PTEN expression was abolished by
si-XIST (Fig. 7b). Results of a CCK-8 assay showed
pcDNA-XIST reduced the growth of HCCLM3 cells,
while pcDNA-XIST + miR-181a mimic increased the pro-
liferation of HCCLM3 cells. Results of the CCK-8 assay
showed that the proliferation of cells with pcDNA-XIST
was significantly reduced compared with that of control
cells. In contrast, overexpression of miR-181a in
HCCLM3 cells could abolish the weakening effects of
pcDNA-XIST (Fig. 7c). The proliferation of cells treated
with siXIST was significantly enhanced compared with
that of control cells, whereas knockdown of miR-181a in
Huh7 cells could abolish the proliferative effects of siXIST
(Fig. 7d). The wound healing assay and Transwell assay
showed that migration and invasion of cells treated with
siXIST was significantly enhanced compared with that of
the control. Meanwhile, knockdown of miR-181a in Huh7
cells abolished the enhancing effects of siXIST on cell mi-
gration and invasion. Moreover, both migration and
Fig. 4 MiR-181a promoted HCC cell invasion and EMT by activating AKT signaling. a The protein expression of EMT related genes (Snail, Slug, N-
cadherin, Vimentin and E-cadherin), MMP-2, and MMP-9. b Western blot analysis of phosphorylated (active) AKT and mTOR in HCC cells trans-
fected with miR-181a mimics or inhibitor. HCC, hepatocellular carcinoma. EMT, epithelial-to-mesenchymal transition. All values are mean ± SD. **
vs NC group, p < 0.01
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invasion of HCCLM3 cells with pcDNA-XIST were sig-
nificantly reduced compared with that of control cells.
Additionally, overexpression of miR-181a in HCCLM3
cells abolished the effects of pcDNA-XIST to reduce cell
migration and invasion (Fig. 7e and f). XIST levels were
significantly decreased in HCC and associated with histo-
logical grade and tumor-node-metastasis stage [19]. These
results indicated that LncRNA XIST and miR-181a could
directly interact with and repress each other, and XIST
could inhibit HCC cell proliferation and metastasis by tar-
geting miR-181a.
Discussion
Hepatocellular carcinoma (HCC) is a serious disease
[20] that is complex and heterogeneous [21]. Difficult
complications of HCC include metastatic lesions and
postsurgical recurrence [22]. Tumor metastasis seriously
affects the prognosis of HCC. Recently, microRNAs have
been discovered to have a role in metastasis and have
been used as cancer-related biomarkers [23]. They are
involved in regulating tumor metastasis via inhibition of
numerous of target genes [24]. The study of Huang et al.
showed that miR-373 and miR-520c could promote
breast cancer invasion and metastasis and are regarded
as metastasis-promoting miRNAs [25]. MicroRNA-34a
inhibits prostate cancer metastases by directly repressing
CD44 [26]. Therefore, we expected to identify micro-
RNAs that regulate HCC metastasis by analyzing micro-
RNA expression profiles. The expression profiles showed
16 miRNAs were down-regulated and 34 miRNAs were
up-regulated.
MicroRNA-181a can promote gastric cancer by nega-
tively regulating tumor suppressor KLF6 [27]. It can
regulate EMT in ovarian cancer, cause hepatitis B virus-
Fig. 5 PTEN is the target gene of miR-181a. a Diagram of the miR-181a putative binding sites and corresponding mutant sites in the 3′-UTR of
PTEN. b Effects of miR-181a on the expression of PTEN 3′-UTR-containing reporter genes. ** vs inhibitor NC or mimics NC, p < 0.01. c and d Protein
expression of PTEN in HCC cells after transfection with miR-181a mimic or inhibitor. e The expression of PTEN in clinical samples with high or low
level of miR-181a. mut, mutant; HCC, hepatocellular carcinoma. ** vs high 181a group, p < 0.01
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Fig. 6 miR-181a is regulated by lncRNA XIST. a Diagram of the three miR-181a putative binding sites and corresponding mutant sites in XIST
mRNA sequences. b Effects of miR-181a on the expression of reporter genes containing wt-XIST or mut-XIST sequences. ** vs Blank, p < 0.01.
c Relative expression of XIST in HCC cells and the normal liver cells. ** vs L-02, p < 0.01. d Relative expression of XIST in HCCLM3 cells after
transfection with miR-181a inhibitor. ** vs Blank, p < 0.01. e Relative expression of miR-181a in Huh7 cells after transfection with si-XIST or
si-Scramble. ** vs Blank, p < 0.01. f Relative expression of miR-181a in HCC clinical samples and the normal. g The relationship between relative
expression of XIST and miR-181a. lncRNA, long non-coding RNA; mut, mutant; wt, wild-type; HCC, hepatocellular carcinoma
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Fig. 7 LncRNA XIST regulates HCC via miR-181a. a and b The regulation of XIST on PTEN was mediated by miR-181a. * vs Blank, p < 0.05. ** vs
Blank, p < 0.01. ## vs miR-181a mimics or miR-181a inhibitor group, p < 0.01. c and d The regulation of XIST on HCC proliferation was mediated
by miR-181a. ** vs si-XIST or pcDNA-XIST group, p < 0.01. ## vs miR-181a mimics or miR-181a inhibitor group, p < 0.01. e and f XIST inhibited the
migration and invasion of HCCLM3 cells, while the transfection of miR-181a mimics abolished the inhibition. lncRNA, long non-coding RNA; HCC,
hepatocellular carcinoma. ## vs si-XIST or pcDNA-XIST group, p < 0.01
Chang et al. BMC Cancer  (2017) 17:248 Page 11 of 14
related HCC, and is related to EpCAM+ HCC cell quan-
tity and tumor initiating ability [28–30]. Among the 34
up-regulated miRNAs identified by analyzing microRNA
expression profiles, we found up-regulation of miR-181a
was the highest. Moreover, the level of miR-181a in
HCC tissues was significantly higher than that in the
normal liver tissues. Hepatitis B virus (HBV) is involved
in the initiation and progression of HCC, the expression
of miR-181a was strongly up-regulated in HBV-
expressing cells or HCC cells [29, 31, 32]. Liu et al. used
miRNA microarrays and northern blotting analyses to
compare the expression profile of cellular miRNAs of a
stable HBV-expressing cell line (HepG2.2.15) and its
parent cell line HepG2, and the results showed that the
expression of miR-181a, miR-181b, miR-200b, and miR-
146a were all up-regulated in HepG2.2.15 cells [33].
Zhuo et al. reported up-regulation of miR-27b, miR-
181a, miR-146b-5p, miR-181d, and miR-146a expression
using real-time RT-PCR in five different drug-resistant
HCC cell sublines [33]. Moreover, the expression of
miR-181a in HCC liver tissues was also up-regulated
compared with the normal cells [34–36]. However,
Elhelw et al. reported that no difference in miR-181a ex-
pression was observed in liver tissues and peripheral
blood mononuclear cell (PBMCs) of patients compared
with controls [37]. Korhan et al. reported miR-181a-5p
is down-regulated in hepatocellular carcinoma and sup-
presses motility, invasion and branching-morphogenesis
by directly targeting c-Met [38]. This may be because in
the study by Elhelw, the tissues collected from HCV-
infected patients may have been the adjacent tissues,
which led to the result that miR-181a expression in the
liver tissues of patients was not different from the con-
trols. Our study showed miR-181a level in HCC tissues
was significantly higher than the normal liver tissues.
That was because some studies have shown that miR-
181a is down-regulated and others have reported the
up-regulation of miR-181a during HCC. Combining this
data with the above research, we confirmed that up-
regulated miR-181a plays a key role in regulating HCC.
Up-regulated miR-181a was reported to promote
tumor metastasis. Our study showed the expression level
of miR-181a in metastatic HCC tissues was significantly
higher than in non-metastatic HCC tissues. Moreover,
the level of miR-181a in stage III and IV tumor was
markedly higher than that in I and II stage. The value in
serum of HCC patients was also much higher than nor-
mal, and the expression of miR-181a was positively re-
lated with AFP level. AFP was reported to be a reliable
serum marker for HCC [39]. Therefore, we concluded
that miR-181a has the potential to be used as a bio-
marker for HCC. We also determined the expression
levels of miR-181a in HCC cell lines with strong or
weak metastasis ability. Results showed the miR-181a
expression in HCC cell lines with strong metastatic
tendencies was significantly higher than in the HCC
cell lines with low metastatic tendencies. Combining
with the result that miR-181a level in metastatic HCC
tissues was significantly higher than in non-metastatic
HCC tissues, we speculated that miR-181a was closely
related to HCC metastasis. Furthermore, we found
that knockdown of miR-181a inhibited the cell prolif-
eration, scratch repair and cell invasion of HCC cells,
whereas overexpression of miR-181a promoted the
cell proliferation, scratch repair and cell invasion. All
those indicated miR-181a expression played a key role
in HCC invasion and metastasis.
EMT is a key factor to embryonic development and
tumor metastasis [7]. Our study showed that the expres-
sion levels of EMT-related protein Slug, Snail, Vimentin,
and N-cadherin in HCC cells decreased markedly after
the knockdown of miR-181a, but the expression of E-
cadherin increased. We concluded that the knockdown
of miR-181a induced the production of EMT, which
plays a key role in tumor metastasis. The levels of
MMP2 and MMP9 decreased with the reduction of FAP
level. MMP2 and MMP9 belong to MMP family, which
have important roles in tumor cell invasion and metasta-
sis [40]. Many studies have shown that there are many
signaling pathways that take part in mediating EMT
[41]. In this study, we tested multiple signaling pathways
that were related to EMT, and interestingly we found
that the PI3K/AKT/mTOR pathway was regulated by
microRNA. The PI3K pathway can regulate survival sig-
nals, prevent the apoptosis of HCC cells, and promote
oncogenic transformation [42–44]. PTEN can be used to
suppress tumors and inhibit the activation of PI3K/AKT
signaling pathway [45]. The loss of PTEN can result in
the activation of AKT kinases, which play key roles in
cell growth, proliferation and invasion [46]. Here, we
identified PTEN as a direct and functional target of
miR-181a. The study showed that overexpression of
miR-181a inhibited the expression of PTEN, and knock-
down of miR-181a promoted its expression. We con-
cluded that up-regulated miR-181a decreased the
expression of PTEN, and the loss of the PTEN activated
PI3K/AKT signaling pathway then promoted the HCC
metastasis in HCC.
Recently, more and more studies have suggested that
microRNAs are regulated by lncRNA. We hypothesized
that the role of miR-181a in promoting HCC metastasis
is regulated by lncRNA. The software analysis found that
miR-181a has multiple binding sites with the lncRNA
XIST. XIST was reported to have key roles in many tu-
mors including testicular germ cell tumors and ovarian
cancer [47]. Our results showed for the first time that
knockdown of XIST up-regulated the level of miR-181a
and knockdown of miR-181a promoted the expression
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of XIST. Moreover, our study showed overexpression of
miR-181a reduced the expression of PTEN, while the
further transfection with pcDNA-XIST abolished this ef-
fect. The proliferation, migration, and invasion of HCC
cells after XIST overexpression were significantly weak-
ened compared with those of control cells. PcDNA-XIST
could reduce the migration and invasion of HCC cells.
After transfection with miR-181a mimics, this effect was
abolished. However, the transfection with miR-181a in-
hibitor abolished the increase effect of siXIST on HCC
cell migration and invasion. We speculated that miR-
181a and XIST are important in the development of
HCC.
Conclusions
Taken together, our study not only revealed the import-
ant role of XIST/miR-181a/PTEN signaling pathway in
HCC pathogenesis, but also implied a potential role for
both miR-181a and XIST in the clinical diagnosis and
treatment of HCC.
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